Background: GCC is a transmembrane cell surface receptor expressed on the apical side of epithelial cell tight junctions in normal intestinal tissue. It is also expressed on approximately 95% of metastatic colorectal cancer (mCRC) tumors, and subsets of gastric and pancreatic cancer. In tumor tissue, epithelial tight junctions are altered, and therefore it is expected that systemically delivered GCC-targeting agents would not affect GCC receptors in normal intestinal tissue but would have access to those in tumor tissue. The investigational antibody-drug conjugate MLN0264 consists of a fully human monoclonal antibody targeting GCC linked to monomethyl auristatin E (MMAE) via a proteasecleavable linker. MMAE and the linker technology are licensed from Seattle Genetics. MLN0264 has shown antitumor activity in xenograft models of GCC-expressing tumors. Methods: The aim of this first-in-human study (NCT01577758) is to evaluate the safety, tolerability, maximum tolerated dose (MTD), and clinical pharmacokinetics (PK) of MLN0264 administered via IV infusion on Day 1 of a 21-day cycle in patients aged ≥18 years with gastrointestinal malignancies expressing GCC who have measurable disease by RECIST and ECOG performance status of 0-1. Dose escalation from 0.3 mg/kg is proceeding via an adaptive Bayesian continual reassessment method in 2-patient cohorts based on dose-limiting toxicities (DLTs) in cycle 1. Approximately 6-10 ascending dose cohorts are anticipated to reach the MTD. Following determination of the MTD, additional mCRC patients will be enrolled for further characterization of MLN0264. Toxicities were graded by NCI-CTCAE v4.03. Blood samples for PK analysis were taken pre-dose and at various time points post dose. Results: As of 18 Jan 2013, 10 patients (male, n = 7; median age 60 [range 30-69 years]) were enrolled and received MLN0264 at 0.3, 0.6, 1.2, 1.5, and 1.8 mg/kg (n = 2 per cohort). Diagnoses include 8 mCRC, 1 pancreatic and 1 esophageal cancer. No DLTs have been observed to date; dose escalation is ongoing. 9 patients reported grade 1 and 2 adverse events (AEs); including diarrhea (50%), fatigue (40%), nausea (20%), pyrexia (20%), anemia (20%), constipation (10%), pain (10%), and dyspnea (10%). No infusion reaction AEs were reported. 3 patients reported grade 3 AEs; including abdominal abscess (10%), anemia (10%), hyponatremia (10%), increased gamma-glutamyltransferase (10%), increased white blood cell count (10%), and intestinal obstruction (10%). No grade 4 AEs have been reported; 3 patients reported unrelated SAEs consisting of intestinal obstruction (n = 1), convulsion (n = 1), and pyrexia (n = 1, occurred twice). Preliminary PK data show that MLN0264 exposure appears greater at increased dose levels. Conclusion: These preliminary data indicate that MLN0264 appears to be generally well tolerated and not associated with infusion reactions within the five dose-escalation
